Kidney cancer reveals its weak link

February 18, 2014, Chalmers University of Technology
This is Jens B Nielsen, professor in Systems Biology, Department of Chemical and Biological Engineering, Chalmers University of Technology. Credit: Peter Widing/Chalmers University of Technology

A team of researchers at Chalmers University of Technology has found that kidney cancer cells have a quite different metabolism than other types of malignancies. The findings pave the way for new methods of diagnosing kidney cancer at an early stage, a feat that had eluded researchers earlier, and thereby fresh approaches to treatment.

Cancer is a result of mutations in the genes of healthy cells. The transition to involves a fundamental transformation of their , the way that they use nourishment and energy. The uninhibited growth of cancer cells is based on their particular metabolism.

The Chalmers researchers have explored the metabolism associated with ten types of cancer cells. When analyzing regulation of metabolism by healthy cells after having become malignant, the researchers made an unexpected discovery.

"One type of cancer stood out from all the rest," says Professor Jens Nielsen, who headed up the team. "Cells affected by kidney cancer reprogram their metabolism in a very special way, which is the weak link in the disease. What fascinated us most was that we can potentially measure this vulnerability by taking a simple blood sample."

In order to look more closely at possible methods of using metabolism to diagnose renal cell carcinoma – the most common type of kidney cancer – the Chalmers team has begun collaborating with researchers at a hospital in Padua, Italy.

"To determine whether our predictions are valid," Professor Nielsen says, "the hospital will conduct a clinical trial to analyze blood samples and urine specimens from kidney cancer patients. We anticipate that a simple method of deciding whether someone has kidney cancer will be available within a few years."

Early detection of kidney cancer significantly improves its prognosis. Surgery to prevent the malignancy from metastasizing can still be successful at that point. The study also suggests that a feasible long-term goal is the ability to destroy cancer cells by changing their metabolism.

"Because kidney cancer cells metabolize abnormally, they have to fight for their survival," says Francesco Gatto, who constructed the cell models. "As a result, it should be possible to customize a way of taking advantage of their vulnerabilities so as to kill them without damaging ."

With that idea in mind, the Chalmers team is also collaborating with British researchers to identify the mechanisms decisive to destroying cells. The objective is to discover and develop drugs that can attack .

The study has been published in the Proceedings of the National Academy of Sciences.

Explore further: Cancerous cells from donor kidney linked to recipient skin cancer

More information: Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma, www.pnas.org/cgi/doi/10.1073/pnas.1319196111

Related Stories

Cancerous cells from donor kidney linked to recipient skin cancer

August 27, 2013
Patients that receive kidney transplants have an increased risk of an invasive form of skin cancer. It is unclear if donor tissue contributes to cancer formation.

Trio of biomarkers may help identify kidney cancer in early stages

March 11, 2013
A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer, according to data published in Cancer Epidemiology, Biomarkers & ...

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

Aspirin and resveratrol could prevent cancer by killing tetraploid cells, research shows

February 11, 2014
(Medical Xpress)—Aspirin and resveratrol kill tetraploid cells in mice and humans, according to a study by Guido Kroemer of the Gustave Roussy Institute in Villejuif, France and his colleagues. Precancerous lesions often ...

Researchers find protein target for anaplastic thyroid carcinoma

February 17, 2014
Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for ...

Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize

April 19, 2013
Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.